Cargando…
Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan
Anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME) improves visual acuity. However, repeated injections during routine outpatient visits are required to maintain this effect. The recent sudden global outbreak of coronavirus disease 2019 (COVID-19) had a major imp...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696996/ https://www.ncbi.nlm.nih.gov/pubmed/36431271 http://dx.doi.org/10.3390/jcm11226794 |
_version_ | 1784838449324359680 |
---|---|
author | Komori, Ryohei Takamura, Yoshihiro Yamada, Yutaka Morioka, Masakazu Matsubara, Hisashi Hirano, Takao Mitamura, Yoshinori Shimizu, Miho Kusuhara, Sentaro Murakami, Tomoya Nihei, Ryotaro Ueda, Tetsuo Kunikata, Hiroshi Jujo, Tatsuya Terasaki, Hiroto Nagasato, Daisuke Noda, Kousuke Osaka, Rie Nagai, Kazuki Yoshida, Shigeo Nozaki, Miho Noma, Hidetaka Ishigooka, Gaku Takahashi, Aya Sawada, Osamu Kimura, Kazuhiro Inatani, Masaru |
author_facet | Komori, Ryohei Takamura, Yoshihiro Yamada, Yutaka Morioka, Masakazu Matsubara, Hisashi Hirano, Takao Mitamura, Yoshinori Shimizu, Miho Kusuhara, Sentaro Murakami, Tomoya Nihei, Ryotaro Ueda, Tetsuo Kunikata, Hiroshi Jujo, Tatsuya Terasaki, Hiroto Nagasato, Daisuke Noda, Kousuke Osaka, Rie Nagai, Kazuki Yoshida, Shigeo Nozaki, Miho Noma, Hidetaka Ishigooka, Gaku Takahashi, Aya Sawada, Osamu Kimura, Kazuhiro Inatani, Masaru |
author_sort | Komori, Ryohei |
collection | PubMed |
description | Anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME) improves visual acuity. However, repeated injections during routine outpatient visits are required to maintain this effect. The recent sudden global outbreak of coronavirus disease 2019 (COVID-19) had a major impact on daily life, including medical care, such as the provision of VEGF therapy. We retrospectively investigated the relationship between the number of anti-VEGF injections for DME and the number of new COVID-19-positive patients at 23 centers in Japan. We also surveyed ophthalmologists regarding the impact of the COVID-19 pandemic on anti-VEGF therapy. In the third and fourth waves of the pandemic, when the number of infected patients increased, the number of injections significantly decreased. In the first, third, and fourth waves, the number of injections increased significantly during the last month of each wave. Approximately 60.9% of ophthalmologists reported that the number of injections decreased after the pandemic. Of the facilities, 52.2% extended the clinic visit intervals; however, there was no significant difference in the actual number of injections given between before and after the pandemic. Although the number of injections temporarily decreased, Japanese ophthalmologists maintained the total annual number of anti-VEGF injections for DME during the pandemic. |
format | Online Article Text |
id | pubmed-9696996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96969962022-11-26 Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan Komori, Ryohei Takamura, Yoshihiro Yamada, Yutaka Morioka, Masakazu Matsubara, Hisashi Hirano, Takao Mitamura, Yoshinori Shimizu, Miho Kusuhara, Sentaro Murakami, Tomoya Nihei, Ryotaro Ueda, Tetsuo Kunikata, Hiroshi Jujo, Tatsuya Terasaki, Hiroto Nagasato, Daisuke Noda, Kousuke Osaka, Rie Nagai, Kazuki Yoshida, Shigeo Nozaki, Miho Noma, Hidetaka Ishigooka, Gaku Takahashi, Aya Sawada, Osamu Kimura, Kazuhiro Inatani, Masaru J Clin Med Article Anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME) improves visual acuity. However, repeated injections during routine outpatient visits are required to maintain this effect. The recent sudden global outbreak of coronavirus disease 2019 (COVID-19) had a major impact on daily life, including medical care, such as the provision of VEGF therapy. We retrospectively investigated the relationship between the number of anti-VEGF injections for DME and the number of new COVID-19-positive patients at 23 centers in Japan. We also surveyed ophthalmologists regarding the impact of the COVID-19 pandemic on anti-VEGF therapy. In the third and fourth waves of the pandemic, when the number of infected patients increased, the number of injections significantly decreased. In the first, third, and fourth waves, the number of injections increased significantly during the last month of each wave. Approximately 60.9% of ophthalmologists reported that the number of injections decreased after the pandemic. Of the facilities, 52.2% extended the clinic visit intervals; however, there was no significant difference in the actual number of injections given between before and after the pandemic. Although the number of injections temporarily decreased, Japanese ophthalmologists maintained the total annual number of anti-VEGF injections for DME during the pandemic. MDPI 2022-11-16 /pmc/articles/PMC9696996/ /pubmed/36431271 http://dx.doi.org/10.3390/jcm11226794 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Komori, Ryohei Takamura, Yoshihiro Yamada, Yutaka Morioka, Masakazu Matsubara, Hisashi Hirano, Takao Mitamura, Yoshinori Shimizu, Miho Kusuhara, Sentaro Murakami, Tomoya Nihei, Ryotaro Ueda, Tetsuo Kunikata, Hiroshi Jujo, Tatsuya Terasaki, Hiroto Nagasato, Daisuke Noda, Kousuke Osaka, Rie Nagai, Kazuki Yoshida, Shigeo Nozaki, Miho Noma, Hidetaka Ishigooka, Gaku Takahashi, Aya Sawada, Osamu Kimura, Kazuhiro Inatani, Masaru Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan |
title | Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan |
title_full | Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan |
title_fullStr | Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan |
title_full_unstemmed | Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan |
title_short | Impact of the COVID-19 Pandemic on Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Japan |
title_sort | impact of the covid-19 pandemic on anti-vascular endothelial growth factor therapy for diabetic macular edema in japan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696996/ https://www.ncbi.nlm.nih.gov/pubmed/36431271 http://dx.doi.org/10.3390/jcm11226794 |
work_keys_str_mv | AT komoriryohei impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT takamurayoshihiro impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT yamadayutaka impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT moriokamasakazu impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT matsubarahisashi impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT hiranotakao impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT mitamurayoshinori impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT shimizumiho impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT kusuharasentaro impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT murakamitomoya impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT niheiryotaro impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT uedatetsuo impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT kunikatahiroshi impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT jujotatsuya impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT terasakihiroto impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT nagasatodaisuke impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT nodakousuke impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT osakarie impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT nagaikazuki impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT yoshidashigeo impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT nozakimiho impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT nomahidetaka impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT ishigookagaku impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT takahashiaya impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT sawadaosamu impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT kimurakazuhiro impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan AT inatanimasaru impactofthecovid19pandemiconantivascularendothelialgrowthfactortherapyfordiabeticmacularedemainjapan |